ArticleInternational journal of women's health2026
Evaluation of the TCGA-Surrogate (ProMisE) Molecular Classification and Clinical Features of Endometrial Carcinoma: A Study of 97 Cases from China.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Molecular classification of endometrial carcinoma (EC) has gained prominence. This study is a retrospective analysis exploring the value of molecular classification in clinical practice in a Chinese cohort. Methods: Ninety-seven patients with EC were enrolled in this study. Patient-derived EC samples were used for polymerase-ɛ exonuclease domain mutation (POLE edm) sequencing. The presence and defects of mismatch repair (MMR) proteins were identified using immunohistochemistry (IHC). Similarly, tumour protein 53 (p53) was identified using IHC. Recurrence-free survival (RFS) was tested between groups using Kaplan-Meier curves with the Log rank test. Results: Distribution by molecular subtype was as follows: POLE edm (3 patients; 3.1%); MMR deficient (MMRd) (32 patients; 33%); abnormal p53 (p53abn) (49 patients; 50.5%) and wild-type p53 (p53wt) (13 patients; 13.4%). Actual RFS rates for the different molecular subtypes were as follows: POLE edm (100%); MMRd (93.5%); p53abn (77.8%) and p53wt (84.6%). Differences in morphology, myometrial invasion, cervical stromal invasion and lymphovascular space invasion among groups were not significant ( Conclusion: Our results suggest that cervical stromal invasion in EC may have no prognostic significance, the EC ProMisE classifier has no relationship with morphology and routine use of molecular classification is premature. The study was limited by a relatively small sample size and short follow-up duration, and further multicenter studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.